MARLBOROUGH, Mass., May 12, 2020 /PRNewswire/ — CardioFocus, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the next-generation HeartLight X3 Endoscopic Ablation System for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation (PAF).
MARLBOROUGH, Mass., February 4, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced that the company has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the HeartLight X3 Endoscopic Ablation System for the treatment of AFib. This supplement […]
CardioFocus® Names Burke T. Barrett as Chief Executive Officer
MARLBOROUGH, Mass., January 22, 2020 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the Company’s Board of Directors has promoted Burke T. Barrett to the position of Chief Executive Officer (CEO), effective January 19, 2020. Mr. Barrett previously served as CardioFocus’ President and Chief […]
CardioFocus® Treats First Patients with HeartLight® Endoscopic Ablation System in France
MARLBOROUGH, Mass., October 29, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the first patients in France have been treated at the Centre Hospitalier Régional Universitaire (CHRU) of Nancy with the HeartLight® Endoscopic Ablation System as part of an exclusive distribution partnership with MicroPort CRM […]
CardioFocus® Launches 100th HeartLight® Center Worldwide
MARLBOROUGH, Mass., June 18, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that the HeartLight® Endoscopic Ablation System is now offered at more than 100 hospitals worldwide.
CardioFocus® Secures $55 Million In Financing
MARLBOROUGH, Mass., May 28, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the completion of a $55 million round of financing.
MARLBOROUGH, Mass., May 10, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3 System for the treatment of AFib.
MARLBOROUGH, Mass., Mar. 25, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
MARLBOROUGH, Mass., Mar. 5, 2019 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib patient population. The 60 patient, prospective study will be led by Na Homolce Hospital (NHH) […]
CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
MARLBOROUGH, Mass., July 11, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch will be managed in conjunction with its distribution partner JapanLifeline Co., Ltd. (JLL).